Early-Cancer Detection Company iCareDx Announces Corporate Name Change To Acuamark Diagnostics
iCareDx, Inc., a biotechnology company focused on blood-based early detection of cancer, today announced that it has changed its name to Acuamark Diagnostics, Inc. In conjunction with its corporate name change, the Company’s website will be available at www.acuamarkdx.com.
Globally, over 22,000 people die of cancer each day. When cancer is detected at the early stages, survival rates are generally still high. Finding cancer early with an accurate, convenient and affordable technology, and attacking it early, can vastly reduce cancer deaths, and substantially lower cancer-related healthcare expenditures.
Dr. Bernard Peperstraete, CEO of Acuamark Diagnostics, Inc. (formerly iCareDx, Inc.) stated, "Our team is excited to re-brand the Company as Acuamark Diagnostics. The name “Acuamark” incorporates several elements that play to the essence of our corporate mission, and well embodies the progress we have made towards developing an accurate diagnostic screening technology to detect low-abundance tumor markers from liquids at the earliest stages of cancer.”
Dr. Francis Barany, PhD, Professor of Microbiology and Immunology at the Weill Cornell Medicine, and lead inventor of Acuamark Diagnostics’ molecular detection technologies, adds: “In addition, the name Acuamark Diagnostics is a reflection that each cancer leaves a unique watermark in our bodies, and as with a watermark, it is barely visible, requiring one to see it in a different light.”
About Acuamark Diagnostics Inc.
Acuamark Diagnostics is a biotechnology company focused on developing screening tests technologies for blood-based early detection of cancer. Acuamark Diagnostics' technology allows for highly accurate screening of blood to detect cancer markers at the early cancer stages, before the cancer becomes untreatable. Backed by a highly experienced team, it is Acuamark Diagnostics’ mission to contribute to the global battle against cancer by detecting and attacking cancer through high-precision, early detection.
Acuamark Diagnostics, Inc.
Bernard Peperstraete, MD
Chief Executive Officer
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Yokogawa Develops N-IO Standard Field Enclosure and Control System Virtualization Platform18.12.2017 02:00 | Pressemelding
Yokogawa Electric Corporation (TOKYO:6841) announces that it has developed an N-IO standard field enclosure and a control system virtualization platform. The enclosure is a weatherproof remote IO cabinet that stores IO devices used by the CENTUM(R) VP integrated production control system and the ProSafe(R)-RS safety instrumented system, and the virtualization platform enables the control of multiple virtual devices on a single server. By reducing the amount of time and effort to engineer a new system, these solutions help to both speed up project execution and reduce total cost of ownership (TCO). The N-IO standard field enclosure is scheduled to be released in February 2018, and the virtualization platform will be released in May 2018. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171217005010/en/ N-I
Celltrion Receives Positive CHMP Opinion for Herzuma® for Trastuzumab Biosimilar15.12.2017 22:13 | Pressemelding
Celltrion, Inc. (KOSDAQ: 068270) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that Herzuma® (trastuzumab biosimilar) be granted marketing authorization in the European Union (EU) for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification. The CHMP’s opinion will now be sent to the European Commission (EC) for final review. Herzuma® is a biosimilar to Herceptin®i, a breast cancer and gastric cancer treatment antibody biologic drug developed by Genentech and marketed by Roche. Herceptin® is a blockbuster drug which had worldwide sales of CHF 6.8 billionii (US$6.8 billion) in 2016, of which CHF 2.1 billioniii (US$2.1 billion) was in
Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease15.12.2017 12:34 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in conjunction with the Committee for Advanced Therapies (CAT), has adopted a positive opinion recommending a marketing authorization (MA) for investigational compound Cx601 (darvadstrocel). Cx601 is expected to be indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.2 This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP opinion in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/201712
Bitcoin Romania and Twispay Announce Integration Partnership Providing Users with the Ability to Purchase Bitcoin with Bank Cards15.12.2017 12:21 | Pressemelding
Bitcoin Romania, leading Eastern European Bitcoin exchange & brokerage firm, and Twispay, Swiss-owned European payment processor and FinTech pioneer, today announced the availability of a payment integration that allows a global clientele to acquire Bitcoin and Ethereum cryptocurrencies using Visa and Mastercard bank cards. Unprecedented in Romania, this is one of the first East-Central European integration partnerships that allow consumers to use their cards to purchase cryptocurrency. Until recently, investors could only acquire cryptocurrencies through bank transfers and cash deposits, but the volatility of cryptocurrency markets dictates the need for additional operational flexibility. Investors require faster, safer, more reliable, and more comfortable ways to complete purchases. “One minute can make the difference between a million lost and a million earned. That is pr
Upon Conclusion of the Fourth Annual Forum for Promoting Peace in Muslim Societies, Scholars and Intellectuals Visit the Louvre Abu Dhabi Museum15.12.2017 11:38 | Pressemelding
A high-level delegation of dignitaries, scholars and intellectuals participating in the fourth annual Forum for Promoting Peace in Muslim Societies, visited the Louvre Abu Dhabi museum. The delegation was headed by H.E Mustafa Ceric, former Grand Mufti of Bosnia; alongside Sheikh Mohammad Mukhtar Ould Imbala, Head of Mauritania’s Fatwa & Grievances Supreme Council; H.E Amar Mirghani Hussein, Sudanese Minister of (religious) Guidance and Endowments; and H.E Salho Jay, Imam of the Juma Masjid in South Africa. The Forum was held in Abu Dhabi from 11-13 December 2017, with the participation of more than 700 scholars, intellectuals and religious dignitaries from around the world. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171215005255/en/ Group Photo of the Scholars and Intellectuals during their visit to the L
Kennedy Wilson Acquires 124-Unit Northbank Apartments in Dublin, Ireland for €45 Million15.12.2017 11:00 | Pressemelding
Global real estate investment company Kennedy Wilson (NYSE: KW) announces that it has acquired Northbank Apartments, a wholly-owned 124-unit apartment community in Dublin’s North Docks, for €45 million from Jarmar Properties Limited (In Receivership) acting through David Carson of Deloitte as Statutory Receiver, the lender being the National Asset Management Agency (“NAMA”). Situated in Dublin’s North Docks, Northbank is located just 50 meters from Kennedy Wilson’s existing 84-unit Liffey Trust apartments. The two buildings benefit from great transport links as the LUAS Red line is immediately adjacent connecting to Dublin’s city centre and main train stations in five minutes. “The successful acquisition of Northbank in such close proximity to our Liffey Trust asset allows us to leverage our existing presence and implement our value-add asset management strategy, including a
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom